# Robert S. Busch

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-s-busch/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,815 |
| Field | Diabetes Treatment and Management |
| h-index | 25 |
| i10-index | 46 |
| Last Known Institution | Albany College of Pharmacy and Health Sciences |
| OpenAlex ID | https://openalex.org/A5103165011 |
| ORCID iD | 0000-0002-7172-2815 |
| Works | 102 |

## Researcher papers

- [Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial](https://scholariq.org/papers/dulaglutide-versus-insulin-glargine-in-patients-with-type-2-diabetes-and/)
- [Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial](https://scholariq.org/papers/atrasentan-and-renal-events-in-patients-with-type-2-diabetes-and-chronic-kidney/)
- [Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial](https://scholariq.org/papers/oral-semaglutide-versus-empagliflozin-in-patients-with-type-2-diabetes/)
- [Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial](https://scholariq.org/papers/semaglutide-once-weekly-as-add-on-to-sglt-2-inhibitor-therapy-in-type-2-diabetes/)
- [Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-semaglutide-in-patients-with-type-2-diabetes-and/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-3/)
- [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-by-sodium/)
- [Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial](https://scholariq.org/papers/effects-of-semaglutide-with-and-without-concomitant-sglt2-inhibitor-use-in/)
- [Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial](https://scholariq.org/papers/effects-of-dapagliflozin-on-mortality-in-patients-with-chronic-kidney-disease-a/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

## Researcher university

- [Albany College of Pharmacy and Health Sciences](https://scholariq.org/institutions/albany-college-of-pharmacy-and-health-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.